熱門資訊> 正文
Lixte Biotechnology任命Jan Schellens为CMO
2024-06-03 22:21
- Lixte Biotechnology Holdings Inc Warrants (01/01/2025)(LIXTW) 0
- Lixte Biotechnology Holdings(LIXT) 0
- LIXTE Biotechnology Holdings(NASDAQ:LIXT) has announced the appointment of Jan Schellens, M.D., Ph.D., as CMO.
- He assumes the CMO role at LIXTE effective Aug. 1, 2024, succeeding James S. Miser, M.D., who is leaving the Co. after serving in this capacity since 2020.
- "He brings a highly relevant background to LIXTE, and we are fortunate in attracting him to our organization, as we continue to make progress with LB-100 to enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer." said Bas van der Baan, LIXTE’s CEO.
More on Lixte Biotechnology Holdings, Inc.
- Lixte stock soars on preclinical data for lead drug LB-100
- Financial information for Lixte Biotechnology Holdings, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
